What Hinge Bio does

Hinge Bio, Inc. is a privately held, clinical-stage biotechnology company founded in 2021 and headquartered in Redwood City, California. The company develops multivalent, multispecific antibody-based therapeutics using its proprietary GEM-DIMER™ platform, which enables combination of multiple fully active antigen-binding fragments into a single molecule with cooperative binding for enhanced biological activity.

Its lead program, HB2198, is a dual CD19/CD20-targeting antibody with dual Fc domains designed to achieve deep (>99%) B cell depletion for an immune reset in B cell-mediated autoimmune disorders, initially Systemic Lupus Erythematosus (SLE) and Lupus Nephritis. The company highlights a differentiated safety profile versus CAR-T and T cell engagers, achieved through immune effector engagement without T cell activation. The FDA cleared the HB2198 IND in October 2025, and Hinge Bio initiated two Phase 1 trials—with the first subject dosed in April 2026.

Hinge Bio is pre-revenue and operates a partnership-based business model, generating value through upfront licensing fees, development and sales milestones, and future royalties from regional commercialization partners. Its first commercial agreement, with Kyorin Pharmaceutical (September 2025), covers development and commercialization of HB2198 in Japan, with Hinge Bio retaining global (ex-Japan) rights. The company was financed by a $30 million Series A in January 2025 led by Point72, alongside Ridgeback Capital, InVivium Capital, and Lightswitch Capital.

Name

Hinge Bio

Legal name

Hinge Bio, Inc.

Website

https://hingebio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Hinge Bio is a clinical-stage biotechnology company developing multivalent, multispecific antibody therapeutics via its proprietary GEM-DIMER platform. Its lead program, HB2198, targets CD19 and CD20 to deeply deplete B cells in autoimmune diseases such as SLE and Lupus Nephritis.

Ownership category

akta.pro rank

Product category

Bispecific Antibody Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Bispecific antibody therapeutics
• B cell depletion therapies
• Multispecific antibody platform
• Autoimmune disease therapeutics
• Clinical-stage biotechnology

Headquarters

HQ city

Burlingame

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing and Milestone Payments: Pre-revenue biotech company expecting to generate revenue through licensing deals, upfront payments, and milestone payments from pharmaceutical partners. The Kyorin collaboration includes $10 million upfront and up to $95 million in milestone payments for SLE indication plus additional payments for other indications.
2. Sales Royalties: Royalty payments from commercialization partners on net sales of approved therapeutics. The Kyorin deal includes tiered sales royalties for HB2198 sales in Japan.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Hinge Bio is a privately-held, clinical-stage biotechnology company that leverages its proprietary GEM-DIMER™ platform to design and develop multivalent, multispecific antibody-based therapeutics. Its lead product candidate, HB2198, is a dual CD19/CD20-targeting B cell-depleting agent with enhanced immune effector engagement, intended to achieve deep (>99%) B cell depletion and immune reset in B cell-mediated autoimmune diseases such as Systemic Lupus Erythematosus and Lupus Nephritis. The company develops drug candidates through clinical stages and partners with larger pharmaceutical companies for regional commercialization, currently demonstrated by its license and collaboration with Kyorin Pharmaceutical for Japan.

Product overview

Hinge Bio is a biotechnology company leveraging its proprietary GEM-DIMER™ platform to develop the next generation of multivalent, multispecific antibody-based therapeutics. The company's lead product candidate is HB2198, a B cell-depleting agent designed for autoimmune diseases, particularly Systemic Lupus Erythematosus (SLE) and Lupus Nephritis. The GEM-DIMER platform enables the creation of therapeutics that combine multiple fully-active antibodies into single molecules with enhanced biological activity, while HB2198 represents the first clinical-stage program emerging from this platform, targeting both CD19 and CD20 with dual Fc domains for superior immune effector cell engagement.

Differentiator

Problem solved

Functional benefit

Products and services

• GEM-DIMER™ Platform A proprietary technology platform that creates multivalent, multispecific antibody-based therapeutics designed to bind targets cooperatively for enhanced biological activity and unique functionality. The platform enables combining multiple fully-active antibodies into a single molecule with entirely new functionality for superior safety and efficacy.
• HB2198 A novel B cell-depleting therapy targeting both CD19 and CD20 with enhanced dual Fc domains for enhanced immune effector cell engagement. Designed to achieve rapid and deep (>99%) depletion of B cells to reset the immune system in B cell-mediated autoimmune disorders such as Systemic Lupus Erythematosus (SLE) and Lupus Nephritis, without the challenges and toxicities associated with CAR-T or T cell Engagers.

Quantifiable outcome

• >99% B cell depletion demonstrated in preclinical in vivo studies
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Kyorin Pharmaceutical Co., Ltd.coreStrategic or Co-development Partner · 30 September 2025License and collaboration agreement for development and commercialization of HB2198 in Japan for multiple autoimmune indications starting with Systemic Lupus Erythematosus. Hinge Bio receives $10 million upfront and is eligible for up to $95 million in milestone payments for SLE indication plus additional payments for other indications. Kyorin funds development, regulatory, marketing and commercialization activities in Japan and contributes to global development. Joint Steering Committee established.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sana Biotechnology: Clinical-stage biotech developing cell-based and in vivo gene therapy approaches for autoimmune disease, including deep B cell depletion strategies. CMO Paul Brunetta previously led autoimmune development at Sana — a direct precedent for the type of therapy HB2198 competes with.
• Harpoon Therapeutics (Merck): Clinical-stage biotech developing T cell engagers and multispecific antibodies (acquired by Merck for $680M). Hinge Bio's VP of CMC previously led CMC at Harpoon — a direct comparator for the multispecific antibody development model and platform-company exit pathway.
• Cabaletta Bio: Clinical-stage biotech developing CAR-T therapies (e.g., CABA-201) for B cell-mediated autoimmune diseases including SLE and lupus nephritis. Same indication focus and immune-reset thesis as HB2198, via a cell therapy modality.
• Zymeworks: Clinical-stage biotech with proprietary multispecific antibody platforms (Azymetric, EFECT) developing bispecific therapeutics for cancer and autoimmune indications. Directly comparable as a multispecific antibody platform company at similar development stage.
• Kyverna Therapeutics: Clinical-stage company developing CAR-T cell therapies for autoimmune diseases including lupus. Directly competes with Hinge Bio's B cell depletion thesis in lupus, though via a CAR-T modality rather than an off-the-shelf antibody.

Broad incumbents

• Genentech (Roche): Developer of the leading anti-CD20 franchise (rituximab, ocrelizumab, obinutuzumab) which Hinge Bio explicitly aims to displace in autoimmune disease. Also operates broad multispecific antibody R&D. CMO Paul Brunetta was previously Global Head of Anti-CD20 at Genentech.
• Regeneron Pharmaceuticals: Large incumbent with bispecific antibody platform (linvoseltamab, odronextamab) and deep CD20 franchise (rituximab partnership via Sanofi historically). Directly relevant as a bispecific/multispecific antibody developer and autoimmune competitor to Hinge Bio's GEM-DIMER approach.

Emerging players

• Compass Therapeutics: Clinical-stage biotech with a proprietary bispecific antibody platform (CTX-009, CTX-112) targeting oncology indications. Comparable multispecific antibody platform developer at similar clinical stage to Hinge Bio.
• Cullinan Oncology: Clinical-stage company developing a portfolio of oncology and immunology therapeutics including multispecific antibodies (e.g., CLN-978). Comparable as a multispecific antibody developer with a diversified pipeline rather than a single-asset focus.

Regional players

• Kyorin Pharmaceutical: Japanese pharmaceutical company that licensed HB2198 for Japan development and commercialization. Acts as both a regional commercialization partner and an industry peer in autoimmune disease drug development across Asian markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hinge-bio-inc/about/?viewAsMember=true

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hinge Bio